Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

NCT02375880 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT02375880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02375880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Lead sponsor
Leap Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
July 31, 2018
Enrollment
51 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, carcinoma of gallbladder, carcinoma of intrahepatic and extra-hepatic biliary system, cholangiocarcinoma